文献速递炎症性肠病

重组带状疱疹疫苗在炎症性肠病患者中的效力

Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-07-15

本研究基于美国退伍军人健康系统回顾性队列,纳入50-60岁和>60岁符合条件的IBD患者分别为7008例和26292例,比较接种与未接种RZV者的带状疱疹发病率。结果显示全程接种后两年龄组带状疱疹粗发病率均低于未接种组,接种与带状疱疹风险显著降低相关。

要点

  • 全程接种RZV后50-60岁组带状疱疹粗发病率为0.00/1000人年,未接种组为3.93/1000人年
  • 全程接种RZV后>60岁组带状疱疹粗发病率为1.80/1000人年,未接种组为4.57/1000人年
  • RZV接种与50-60岁及>60岁IBD患者带状疱疹风险显著降低相关

核心结论

  • RZV接种与50-60岁及>60岁IBD患者带状疱疹感染风险降低相关。
  • 应加大努力为所有IBD患者接种RZV。

研究设计与样本

  • 回顾性队列研究,数据来自美国国家退伍军人健康系统。
  • 纳入2018年1月3日或之前诊断为IBD的患者,50-60岁组7008例,>60岁组26292例。
  • 采用多变量Cox回归含时变分析,比较接种(全程和单剂分别)与未接种者的带状疱疹风险,并按IBD药物分层。

主要发现

  • 全程接种RZV后带状疱疹粗发病率在50-60岁组为0.00 vs 未接种组3.93/1000人年,>60岁组为1.80 vs 4.57/1000人年。
  • RZV接种与50-60岁和>60岁年龄组带状疱疹风险显著降低相关,但受带状疱疹事件率低限制。

临床怎么用

  • 建议为所有IBD患者接种RZV以降低带状疱疹风险。

局限性

  • 带状疱疹事件率低限制了结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Individuals with inflammatory bowel disease (IBD) have an increased risk of herpes zoster (HZ) infection. Although the efficacy of recombinant zoster vaccine (RZV) is high among immunocompetent individuals, little is known about its effect among immunosuppressed individuals with IBD. METHODS: We conducted a retrospective cohort study among individuals in the national Veterans Affairs Healthcare System diagnosed with IBD on or before January 3, 2018, the earliest date of RZV vaccinations. We collected data on 7008 and 26,292 eligible patients with IBD in the 50- to 60-year and >60-year age groups, respectively. We identified veterans who received RZV and compared the incidence of HZ between vaccinated versus unvaccinated individuals. We performed multivariable Cox regression with time varying analysis to determine the risk of HZ among the vaccinated (full dose and single dose separately) versus unvaccinated cohort, stratified by IBD medications. RESULTS: The crude HZ incidence rate after full dose vaccination of RZV when compared with the unvaccinated group was lower in both the 50- to 60-year age group (0.00 vs 3.93 per 1000 person-years) and >60-year age group (1.80 vs 4.57 per 1000 person-years). RZV vaccination was associated with a significantly lower risk of HZ among the 50- to 60-year and >60-year age groups, although this was limited by low HZ event rates. CONCLUSION: RZV vaccination was associated with decreased risk of HZ infection among both the 50- to 60-year and >60-year age groups. Greater efforts should be made to vaccinate all patients with IBD with RZV.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Khan N, Wang L, Trivedi C, et al. Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2021. PMID: 34274513. doi:10.1016/j.cgh.2021.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。